

Fertility Care for Perimenopausal and Menopausal Women

(continued from page 24)

5. Faddy MJ, Gosden RG, Gougeon A, et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. *Hum Reprod* 1992;7:1342-46.

6. Faddy MJ, Gosden RG. A mathematical model of follicle dynamics in the human ovary. *Hum Reprod* 1995; 10:770-75.

7. Klein NA, Soules MR. Endocrine changes of the perimenopause. *Clin Obstet Gynecol* 1998;41:912-20.

8. Macklon NS, Fauser BC. Ovarian reserve. *Semin Reprod Med*. 2005;23:248-56.

9. Santoro N, Brown JR, Adel T, et al. Characterization of reproductive hormonal dynamics in the perimenopause. *J Clin Endocrinol Metab* 1996;81:1495-501.

10. Klein NA, Battaglia DE, Fujimoto Y, et al. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. *J Clin Endocrinol Metab* 1996; 81:1038-45.

11. Klein NA, Illingworth PJ, Groome NP, et al. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. *J Clin Endocrinol Metab* 1996;81:2742-45.

12. Danforth DRP, Arbogast LK, Mroueh J, et al. Dimeric inhibin: a direct marker of ovarian aging. *Fertil Steril* 1998; 70:119-23.

13. Groome NP, Illingworth PJ, O'Brien M, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. *J Clin Endocrinol Metab* 1996;81:1401-5.

14. Santoro N, Adel T, Skurnick JH. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. *Fertil Steril* 1999;71:658-62.

15. Soules MR, Battaglia DE, Klein NA. Inhibin and reproductive aging in women. *Maturitas* 1998;30:193-204.

16. van Zonneveld P, Scheffer GJ, Broekmans FJ, et al. Do cycle disturbances explain the age-related decline of female fertility? Cycle characteristics of women aged over 40 years compared with a reference population of young women. *Hum Reprod* 2003;18:495-501.

17. Volarcik K, Sheehan L, Goldfarb J, et al. The meiotic competence of in-vitro matured human oocytes is influenced by donor age: evidence that folliculogenesis is compromised in the reproductively aged ovary. *Hum Reprod* 1998;13:154-60.

18. Benadiva CA, Kligman I, Munne S. Aneuploidy 16 in human embryos increases significantly with maternal age. *Fertil Steril* 1996;66:248-55.

19. Batista MC, Zellmer AW, Merino MJ, et al. Effects of aging on menstrual cycle hormones and endometrial maturation. *Fertil Steril* 1995;64:492-99.

20. Martin JS, Nisker JA, Tunmon IS, et al. Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels. *Fertil Steril* 1996;65:1238-40.

21. Kline J, Kinney A, Kelly A, et al. Predictors of antral follicle count during the reproductive years. *Hum Reprod* 2005;20:2179-89.

22. Scheffer GJ, Broekmans FJ, Dorland M, et al. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. *Fertil Steril* 1999;72:845-51.

23. Ng EH, Chan CC, Tang OS, et al. Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment. *Hum Reprod* 2005;0:1647-54.

24. Hendriks DJ, Broekmans FJ, Bancsi LF, et al. Repeated clomiphene citrate challenge testing in the prediction of outcome in IVF: a comparison with basal markers for ovarian reserve. *Hum Reprod* 2005;20:163-9.

25. Seifer DB, Gardiner AC, Lambert-Messerlian G, et al. Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. *J Clin Endocrinol Metab* 1996;81:736-39.

26. Fanchin R, Schonauer LM, Righini C, et al. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. *Hum Reprod* 2003;18:323-27.

27. Seifer DB, MacLaughlin DT, Christian BP, et al. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. *Fertil Steril* 2002;77:468-71.

28. Eldar-Geva T, Ben-Chetrit A, Spitz IM, et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. *Hum Reprod* 2005;20:3178-83.

29. Elizur SE, Lerner-Geva L, Levron J, et al. Factors predicting IVF treatment outcome: a multivariate analysis of 5310 cycles. *Reprod Biomed Online* 2005;10:645-49.

30. Lass A, Croucher C, Duffy S, et al. One thousand initial-

ed cycles of in vitro fertilization in women ≥ 40 years of age. *Fertil Steril* 1998;70:1030-34.

31. Cahill DJ, Prosser CJ, Wardle PG, et al. Relative influence of serum follicle stimulating hormone, age and other factors on ovarian response to gonadotrophin stimulation. *Br J Obstet Gynaecol* 1994;101:999-1002.

32. Kailasam C, Keay SD, Wilson P, et al. Defining poor ovarian response during IVF cycles, in women aged < 40 years, and its relationship with treatment outcome. *Hum Reprod* 2004;19:1544-47.

33. Lashen H, Ledger W, Lopez-Bernal A, et al. Poor responders to ovulation induction: is proceeding to in-vitro fertilization worthwhile? *Hum Reprod* 1999;14:964-69.

34. Guzik DS, Carson SA, Coutifaris C, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. *N Engl J Med* 1999;340:177-83.

35. Wolf LJM. Ovulation induction. *Clin Obstet Gynecol* 2000;43:902-15.

36. Awonuga AO, Nabi A. In vitro fertilization with low-dose clomiphene citrate stimulation in women who respond poorly to superovulation. *J Assist Reprod Genet* 1997;14:503-7.

37. Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. *Fertil Steril* 2002;77:776-80.

38. Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. *J Soc Gynecol Investig* 2004;11: 406-15.

39. Sauer MV, Paulson RJ, Ary BA, et al. Three hundred cycles of oocyte donation at the University of Southern California: assessing the effect of age and infertility diagnosis on pregnancy and implantation rates. *J Assist Reprod Genet* 1994;11:92-6.

40. Sauer MV, Paulson RJ, Lobo RA. Pregnancy after age 50: application of oocyte donation to women after natural menopause. *Lancet* 1993;341:321-23.

41. Yaron Y, Amit A, Brenner SM, et al. In vitro fertilization and oocyte donation in women 45 years of age and older. *Fertil Steril* 1995;63:71-6.

42. Legro RS, Wong IL, Paulson RJ, et al. Recipient's age does not adversely affect pregnancy outcome after oocyte donation. *Am J Obstet Gynecol* 1995;172(1 Pt 1):96-100.

43. US Centers for Disease Control and Prevention. 2003 Assisted Reproductive Technology (ART) Report. (Online at www.cdc.gov/ART/ART2003) [accessed February 3, 2006]

44. Antinori S, Gholami GH, Versaci C, et al. Obstetric and prenatal outcome in menopausal women: a 12-year clinical study. *Reprod Biomed Online* 2003;6:257-61.

45. Paulson RJ, Hatch IE, Lobo RA, et al. Cumulative conception and live birth rates after oocyte donation: implications regarding endometrial receptivity. *Hum Reprod* 1997;12:835-39.

46. Pena JE, Chang PL, Chan LK, et al. Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles. *Hum Reprod* 2002;17:83-7.

47. Sauer M, Cohen MA. Egg and embryo donation. In Garner DK, Weissman A, Howles CM, et al., eds. *Textbook of assisted reproductive techniques*. New York, Taylor & Francis;2004:843-54.

48. Reynolds MA, Schieve LA, Jeng G, et al. Risk of multiple birth associated with in vitro fertilization using donor eggs. *Am J Epidemiol* 2001;154:1043-50.

49. Johnson J, Bagley J, Skaznik-Wikiel M, et al. Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. *Cell* 2005;122:303-15.

ADVERTISERS' INDEX

Duramed Pharmaceuticals, Inc. A subsidiary of Barr Laboratories Inc.

Enjuvia.....8-9

Enzymatic Therapy

Remifemin13

Pfizer Inc.

Estring.....3-4

Sepracor Inc.

LunestaIBC, OBC

Wyeth Pharmaceuticals

PremarinIFC, 1